Grifols, S.A. Earnings Recaps
Q1 2026
May 11, 2026
Shares declined 1.2% following the quarter, reflecting investor caution despite results largely in line with prior guidance and steady margins, with market focus likely on the cautious outlook and incremental execution challenges ahead. The market reaction suggests investors remain cautious on the outlook and any incremental pressure on margin expansion or growth acceleration.
Key takeaways
- Revenue reached EUR 1.7 billion, up 3.3% at constant currency, driven primarily by a nearly 7% growth in the Biopharma segment, notably from the immunoglobulin franchise.
- Adjusted EBITDA stood at EUR 404 million (constant currency), with margins broadly stable year-over-year, signaling no immediate margin expansion despite strategic efforts.
- Free cash flow improved by EUR 30 million, with leverage stable at 4.3x, consistent with typical seasonal patterns.
- The company confirmed ongoing execution of five strategic pillars, including ramping up its Egypt plasma platform to reduce sourcing costs and optimize the global plasma supply chain.
- Diagnostics revenue declined on a reported basis due to the dissolution of a joint venture, though underlying business showed low single-digit growth on a like-for-like basis.
Q3 2025
Nov 7, 2025
Grifols delivered solid third-quarter performance with 7.7% revenue growth year-over-year, reflecting strong demand and effective cost management while facing external pressures.
Key takeaways
- Year-to-date revenue reached EUR 5.5 billion, with a 10.5% increase on a like-for-like basis at constant currency.
- Adjusted EBITDA for the third quarter was EUR 482 million, contributing to a total of EUR 1,358 million year-to-date, up 11.2% year-over-year.
- Free cash flow improved significantly to EUR 188 million, marking a EUR 257 million increase versus the previous year.
- Leverage ratio improved nearly 1x year-over-year to 4.2x, reflecting the company’s commitment to deleveraging.
- Grifols remains on track to launch its fibrinogen therapy in Europe by late 2025 and is advancing strong clinical pipelines despite regulatory complexities.